With the 3M™ V.A.C.® Ulta Therapy System

A world leader in skin and wound care right by your side

Science-based solutions

Our comprehensive portfolio of advanced wound care solutions is at the forefront of innovation.

Ongoing support

Our team is available to assist with clinical and technical support.

World-class education

Empowering you with hands-on training and award-winning education.

For more information on the benefits of 3M™ Veraflo™ Therapy, contact your local Representative.

Note: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. This material is intended for healthcare professionals.

©2021 3M. All rights reserved. 3M and the other marks shown are marks and/or registered marks. Unauthorized use prohibited. 70-2013-1241-3 PRA-PM-EU-00528 (12/21)
## Topical wound solutions

The following topical solutions are compatible with 3M™ Veraflo™ Therapy based on 3M in-house testing of the Veraflo Therapy disposables with respect to mechanical properties, biocompatibility, and solution interaction.*

<table>
<thead>
<tr>
<th>Generic solution class</th>
<th>Considerations for use with 3M™ Veraflo™ Therapy</th>
</tr>
</thead>
</table>
| Hypochlorite-based solutions* (e.g. hypochlorous acid, sodium hypochlorite) | • Based on results of compatibility testing, Dakin’s Solution should not be used in concentrations greater than 0.125% (quarter strength).  
• Consider using the fewest irrigation cycles and minimizing hold times to the lowest level that is clinically relevant. |
| Silver nitrate (0.5%) | Silver nitrate is light sensitive. Protect solution container and 3M™ V.A.C. Veralink™ Cassette tubing from light during use of silver nitrate. |
| Biguanides (Polyhexanide) | Solution container can be:  
• Spiked directly.  
• Connected using a spike adapter if available.  
• Transferred to a container having a spike port.  
For compatibility assessment, polyhexanide solution was tested in final concentrations equal to or less than 0.1%. |
| Lidocaine HCl | • For compatibility assessment, lidocaine HCl was tested in final concentrations equal to or less than 0.1% in saline.  
• Toxicity concerns may exist; consult with your pharmacist and/or prescribing physician for solution and patient-specific considerations when using lidocaine HCl as an additive to saline instillation solutions.  
• No device-related considerations for use with Veraflo Therapy. |
| Cationic solutions (Octenidine) | For compatibility assessment, Octenilin® solution was tested in final concentrations equal to or less than 0.05% Octenidine. |
| Isotonic solutions | May need to be connected using a spike adapter. |
| Acetic acid | For compatibility assessment, acetic acid was tested in final concentrations equal to or less than 0.25% in sterile water. |
| Benzalkonium Chloride (0.1%) | For compatibility assessment, benzalkonium chloride was tested in final concentrations equal to or less than 1:200,000 dilution. |

*Hypochlorous acid solutions applied frequently at high concentrations can lead to significant material degradation. Consider utilizing concentrations and exposure durations as low as clinically relevant. Testing indicates that the concentration of hypochlorous acid, a preservative of the solution in the bottle, may be significantly reduced after prolonged contact with the fluid path components of the Veraflo Therapy delivery system. Due to the reactive nature of hypochlorous acid solutions, exposure to the fluid path components of the Veraflo Therapy delivery system may impact the final active or preservative concentration of the solution.

*3M is solely responsible for the solution compatibility information provided herein. Always refer to the solution manufacturer’s prescribing information when deciding whether to administer any solution with the 3M™ V.A.C.® Ulta Therapy System and for appropriate safety, efficacy and dosing information. Listing of specific solutions is not an endorsement of a specific solution or an indication of clinical efficacy or safety.